Literature DB >> 19180895

Methylene blue mediated photodynamic therapy for resistant plaque psoriasis.

Manal Salah1, Nevien Samy, Maha Fadel.   

Abstract

Topical treatment of resistant psoriatic plaque stage lesions may be difficult and the systemic therapies seem inappropriate. Therefore, a topical 0.1% methylene blue (MB) hydrogel was prepared and evaluated for percent drug content, drug uniformity, pH, rheological and organoleptic characters such as feel tackiness, grittiness sensation, and transparency in addition to release kinetics study in vitro. The efficiency of the photodynamic therapy (PDT) of MB photo-activated using 565 mW Light emitting diode (LED) 670 nm was evaluated in patients with resistant plaque psoriasis. The gel was evaluated in single blinded study. The patients were subjected to repeated sessions of irradiation, skin biopsies from each patient in the beginning and at the end of the sessions were taken for histopathological studies. Results showed the hydrogel was transparent nongritty and the drug uniformly dispersed with pH=7.2 and viscosity value=25.04 Pa. The drug content was found to be 99.4 +/- 0.15 %. Drug release was following zero order kinetics with rate constant K=0.348 +/- 0.01 and T(1/2) = 0.95 +/- 0.5 hours. Sixteen patients experienced complete clearance of their treated lesions. Skin appeared normal in color, texture, and pliability with no complications indicating the lack of skin sensitivity. Histopathological examinations showed nearly normal epidermis at the end of all sessions. The authors concluded that the prepared hydrogel was safe, stable, and very effective. The results are encouraging to accept MB as a photosensitizer for PDT and as a safe and effective method for treatment of selected cases of resistant localized psoriasis

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180895

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  9 in total

1.  KGF, FGFb, VEGF, HGF and TGFβ1 secretion of human keratocytes following photodynamic inactivation (PDI) in vitro.

Authors:  Tanja Stachon; Jiong Wang; Timo Eppig; Achim Langenbucher; Markus Bischoff; Berthold Seitz; Nóra Szentmáry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-08       Impact factor: 3.117

2.  [Photodynamic therapy for infectious keratitis].

Authors:  N Szentmáry; S Goebels; M Bischoff; B Seitz
Journal:  Ophthalmologe       Date:  2012-02       Impact factor: 1.059

3.  Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice.

Authors:  Maha Fadel; Kawser Kassab; Doa Abdel Fadeel
Journal:  Lasers Med Sci       Date:  2010-03       Impact factor: 3.161

4.  PharmGKB summary: methylene blue pathway.

Authors:  Ellen M McDonagh; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

5.  Methylene blue: revisited.

Authors:  Prashant R Ginimuge; S D Jyothi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2010-10

6.  Adsorptive removal of methylene blue by agar: effects of NaCl and ethanol.

Authors:  Babak Samiey; Fatemeh Ashoori
Journal:  Chem Cent J       Date:  2012-02-17       Impact factor: 4.215

Review 7.  Chemical and biological mechanisms of pathogen reduction technologies.

Authors:  Janna M Mundt; Lindsay Rouse; Jeroen Van den Bossche; Raymond P Goodrich
Journal:  Photochem Photobiol       Date:  2014-08-20       Impact factor: 3.421

Review 8.  An Update on Photodynamic Therapy of Psoriasis-Current Strategies and Nanotechnology as a Future Perspective.

Authors:  Sebastian Makuch; Mateusz Dróżdż; Alicja Makarec; Piotr Ziółkowski; Marta Woźniak
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

Review 9.  Pore forming channels as a drug delivery system for photodynamic therapy in cancer associated with nanoscintillators.

Authors:  Luiz Anastacio Alves; Leonardo Braga Ferreira; Paulo Furtado Pacheco; Edith Alejandra Carreño Mendivelso; Pedro Celso Nogueira Teixeira; Robson Xavier Faria
Journal:  Oncotarget       Date:  2018-05-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.